Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Record History

See every version on ClinicalTrials.gov ↗

1. Jun 16, 2026 5 versions Re-verified since Aug 1, 2012, no change to tracked fieldsv9-v13
2. Notable Apr 4, 2011 Results first posted: Apr 29, 2011v8 Show 4 more changesShow less

   • Primary endpoint revised
   • Interventions: RAD001 (Drug) to RAD001 (Everolimus) (Drug)
   • Eligibility criteria expanded, about 17 words
   • Study description expanded, about 2 words
3. Notable Oct 23, 2009 Primary endpoint revisedv7 Show 4 more changesShow less

   • Trial status: Active, Not Recruiting to Completed
   • Enrollment target: estimated 25 to confirmed 10
   • Primary and study completion dates changed from estimate of Apr 2010 to Oct 2009
   • Secondary endpoints shortened, about 9 words
4. Notable May 1, 2009 Primary and study completion dates: Apr 2009 to Apr 2010

   • Trial status: Recruiting to Active, Not Recruiting
   • Site details revised
   • Eligibility criteria expanded, about 2 words

   v6
5. Notable Nov 21, 2008 Primary endpoint revisedv5 Show 6 more changesShow less

   • Primary completion date: Apr 2009
   • Secondary endpoint revised
   • Study description shortened, about 19 words
   • Collaborator revised
   • Eligibility criteria shortened, about 2 words
   • Study title expanded, about 1 word

9. Mar 20, 2007 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.